Neumora Therapeutics, Inc. Common Stock
General ticker "NMRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $372.6M (TTM average)
Neumora Therapeutics, Inc. Common Stock follows the US Stock Market performance with the rate: 7.9%.
Estimated limits based on current volatility of 2.6%: low 2.08$, high 2.19$
Factors to consider:
- Total employees count: 124 as of 2023
- Current price 65.9% below estimated low
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.06$, 15.10$]
- 2025-12-31 to 2026-12-31 estimated range: [5.21$, 13.12$]
Short-term NMRA quotes
Long-term NMRA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $135.87MM | $188.19MM | $263.46MM |
| Operating Income | $-135.87MM | $-188.19MM | $-263.46MM |
| Non-Operating Income | $4.97MM | $-47.46MM | $19.86MM |
| R&D Expense | $104.75MM | $142.72MM | $200.93MM |
| Income(Loss) | $-130.90MM | $-235.66MM | $-243.61MM |
| Taxes | $0.00MM | $0.27MM | $0.18MM |
| Profit(Loss)* | $-130.90MM | $-235.93MM | $-243.79MM |
| Stockholders Equity | $-446.85MM | $469.08MM | $287.06MM |
| Assets | $426.23MM | $496.19MM | $316.97MM |
| Operating Cash Flow | $-114.90MM | $-163.28MM | $-182.94MM |
| Capital expenditure | $0.51MM | $0.12MM | $0.00MM |
| Investing Cash Flow | $-168.01MM | $64.39MM | $-70.56MM |
| Financing Cash Flow | $115.74MM | $231.94MM | $21.60MM |
| Earnings Per Share** | $-0.86 | $-1.49 | $-1.53 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.